Opinion|Videos|February 24, 2025
Patient Counseling and Management of Adverse Events
Panelists discuss how pharmacists serve as essential medication experts by providing comprehensive counseling on VMAT2 inhibitors, including proper administration, expectations for symptom improvement, potential side effects, and drug interactions, while playing a vital role in monitoring older adult patients through regular check-ins, medication therapy management services, and collaboration with the healthcare team to optimize treatment outcomes.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- What role do pharmacists play in counseling patients and caregivers about TD treatments, including VMAT2 inhibitors?
- How do pharmacists help monitor for and manage adverse effects associated with TD therapies in older adults?
Advertisement
Related to this article
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Glucose Monitoring: Timing Makes Every Reading Count
2
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
3
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
4
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
5